Usefulness of WBC Count to Mean Platelet Volume Ratio in Predicting Short-Term (30 Days) Major Adverse Cardiac Events in Patients Presenting with Acute Coronary Syndrome and its Comparison in Males and Females

Sheshidhar Madaka¹

¹Department of Cardiology, NIMS Hyderabad, India 628897

Address for correspondence Dr. Sheshidhar Madaka, MD, DM
Resident, Department of Cardiology, NIMS Hyderabad, India
(e-mail: sheshidharmadaka@gmail.com).

Ind J Car Dis Wom 2021;6:88–97.

Abstract

Background: Among cardiovascular illnesses, acute coronary syndrome (ACS) events are associated with higher mortality and morbidity. The mechanism of inflammation involved in the ACS includes atherosclerotic plaque development, followed by development of plaque rupture and thrombosis. The present study is to determine whether white blood cell count to mean platelet volume ratio (WMR) can predict short-term (30 days) major adverse cardiac events (MACE) in ACS patients, and also compare WMR and MACE in males and females.

Aim: To detect usefulness of white blood cell (WBC) count to WMR in predicting short term (30 days) MACE in patients presenting with ACS and compare values and MACE events in males and females.

Material and Methods: The present study was conducted in a tertiary-care hospital from September 2020 to December 2020. A total of 60 patients, who presented with ACS and were undergoing percutaneous coronary intervention (PCI), fulfilled the selection criterion; hence, a total of 60 patients were selected for the study after taking informed consent. The clearance from the Institutional Ethical committee (IEC) was obtained prior to the initiation of the study. All the necessary investigations were done in patients who fulfilled the inclusion criteria. The results of the study were systematically selected and analysis done statistically. The study included all patients with clinical suspicion of ACS for more than 18 years and excluded non-ACS patients, patients with malignancy history, inflammatory diseases, autoimmune disorders, infections, and those who are immunosuppressed.

Keywords

- White blood cell (WBC) to mean platelet volume (MPV) ratio (WMR)
- major adverse cardiac events (MACE)
- acute coronary syndrome (ACS)
- males and females

DOI <https://doi.org/10.1055/s-0041-1732513>

© 2021. Women in Cardiology and Related Sciences.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Results: In the present study, receiver operating characteristic (ROC) curve showed cutoff value of WMR as 1059 with area under curve (AUC) of 0.6 (95% CI 0.4–0.9). MACE occurred in 12 patients and mortality occurred in 6 patients. Among MACE, recurrent myocardial infarction (REMI) occurred in 7 (35%) cases, arrhythmias occurred in 5 (25%), and cardiogenic shock occurred in 8 (40%) cases.

WMR with a cutoff value of 1059 was significant and highly accurate in predicting MACE, with sensitivity of 91.6%, specificity of 87.5%, PPV of 64.7%, NPV of 97.6%, and diagnostic accuracy of 88.3%. Compared to males, females have less sensitivity to, high specificity to, and high diagnostic accuracy of WMR ratio in predicting MACE. MACE did not show any gender predilection.

Conclusion: In patients, who presented with ACS, high WMR values were associated with worse short-term outcomes and independently predicted short-term MACE. Compared to males, females have less sensitivity to, high specificity to, and high diagnostic accuracy of WMR ratio in predicting MACE.

Abstract Image

Introduction

Among cardiovascular illnesses, acute coronary syndrome (ACS) events are associated with higher mortality and morbidity.¹ Majority of the cardiovascular disease risk burden will be taken by the Indian subcontinent in the future.² The mechanism of inflammation involved in ACS includes atherosclerotic plaque development, followed by development of plaque rupture and thrombosis.³

ACS events are not only due to the stenosis of coronary arterial system but also due to other pathophysiological mechanisms involved in the development of acute coronary events. In the development of acute coronary events, leukocytes play an important role through the processes of inflammation.⁴ Macrophages and T-cells, which are located in the atherosclerotic plaque core, get activated when endothelium is injured, and there is release of cytokines and procoagulants by these cells, which promote the thrombus formation. These

mechanisms increase the risk of thrombogenicity and the development of ACS.⁵

Increased leukocyte (white blood cell [WBC]) count is helpful in predicting clinical outcome in patients with ACS.⁶ Mean platelet volume (MPV) is a marker of platelet activation is an inflammatory marker, which can be useful in assessing prognosis in patients with ACS.⁷ As a combination of both these markers (WBC and MPV), WBC count to MPV ratio (WMR) has been recently found as a novel noninvasive marker for predicting long-term outcomes in patients with ACS.⁸ However, the use of this novel marker for assessing prognosis in persons with ACS in Indians is not yet studied. Therefore, in the present study, we are evaluating whether WMR can be useful as a marker of prognosis in Indian persons presenting with ACS.

Aims and Objectives

To detect usefulness of WMR for predicting short-term (30 days) major adverse cardiac events (MACE) in patients presenting with ACS, and also compare values and MACE events in males and females.

Materials and Methods

The present study was conducted in a tertiary care hospital from September 2020 to December 2020. In the present study, the sample size was 60 cases with ACS, which is based on the study by Adam et al, in which the sensitivity of WMR was 69% with mortality rate of 14%, and the minimum sample size required was 25 cases with ACS.⁹ Inclusion criteria include patients with ACS. ACS patients were identified by using the following criteria: non-ST-segment elevated myocardial infarction (NSTEMI) was diagnosed if persons had increased cardiac enzymes without detectable ST-segment elevation on the electrocardiogram (ECG). STEMI was diagnosed if person complained of typical angina which lasted for more than 20 minutes along with any one of the following features: ST-segment elevation of at least 1 mm in two or more contiguous leads, formation of new Q wave or left bundle branch block (LBBB) formation, and/or two times increase in the cardiac enzymes. Unstable angina (UA) is diagnosed if there is detectable ischemic changes on an ECG without cardiac enzymes elevation.¹⁰

A total of 60 patients presenting with ACS, who fulfilled the selection criterion, were studied. The clearance from the Institutional Ethical committee (IEC) was obtained prior to the initiation of the study. Eligible patients for the study were explained about the study and investigations to be conducted, and written informed consent was taken. All the necessary data including age and gender, clinical features, history of diabetes mellitus, hypertension, smoking, alcohol consumption, and tobacco chewing were taken from the eligible patients, and physical examination carried out to assess the vital parameters. Patients were also evaluated for Killip clinical examination classification and New York Heart Association (NYHA) classification.^{11,12}

Laboratory Investigations:

After admission of the patient, blood samples were collected within 30 minutes to measure hematological parameters and conduct biochemical investigations.

An automated hematology analyzer Beckmann Coulter DXH800 was used to measure hematological parameters and liver function tests (LFTs), while serum electrolytes, blood urea nitrogen (BUN) and creatinine (Cr) were measured with Roche Cobas c501 chemistry analyzer. Patients were also evaluated with ischemia markers creatine phosphokinase (CPK), lactate dehydrogenase (LDH), echocardiography, and a 12-lead ECG. Troponin I was measured with Beckmann DXI600.

Electrocardiographic and Enzymatic Analysis:

The eligible patients were subjected to ECG in order to diagnose the type of ACS. A standard 12-lead ECG recorded at a paper speed of 25 mm/sec and at a calibration of 1 mV = 10 mm. STEMI was diagnosed, according to the European Society of Cardiology (ESC) and American College of Cardiology (ACC) criteria, as typical angina lasting longer than 30 minutes, increased creatine kinase-MB (CK-MB) fraction > 200 U/l and/or increased cardiac troponin I more than 2 microgram/L and/ or new ST elevation at the J point in two contiguous leads > 0.2 mV which leads v2-v3 or > 0.1 mV in other leads.^{13,14}

Echocardiography: The patients were evaluated with echocardiography at the time of hospital admission. The left ventricular end-diastolic diameter was measured from the parasternal long axis view, and the left ventricular ejection fraction was measured using the single-plane, Simpson method.

Inclusion Criteria

- All patients with clinical suspicion of ACS are included.
- 18 to 90 years age people are included.
- Both gender are included.

Exclusion Criteria

- Non-ACS patients, patients with malignancy history, inflammatory diseases, autoimmune disorders and infections, and those who are immunosuppressed.

Statistical Analysis

- Data has been collected, compiled using Microsoft Excel, and statistical analyzed with the help of SSPS v20. Results on continuous variables are presented as mean and standard deviation (SD). Results on categorical variables are presented as percentages. Chi-square test is used to find out the significance of study parameters on a categorical scale between two investigations. Receiver operating characteristic (ROC) curve analysis was conducted to determine prognostic accuracy of WMR in predicting MACE. Continuous variables are analyzed using independent t-tests for normal distribution; otherwise, the Mann-Whitney U-test is employed. All *p*-values are two-tailed, and *p* < 0.05 is considered statistically significant.

Results

In this study, a total of 60 patients with ACS were enrolled.

We observed a slightly greater number of males ($n = 36$, 60%) than females ($n = 24$, 40%) in the present study, as shown in ►Table 1.

Comorbidities of patients: Among 60, 36 (60%) had hypertension and 24 did not have hypertension, 21 (35%) were diabetic, 26 (43.3%) were alcoholics, 21 (35%) were smokers, and 10 (16.67%) had hypothyroid, as shown in ►Table 2.

Diagnosis of patients: Out of 60 patients presenting with ACS, 9 had anterior wall myocardial infarction (AWMI), 8 presented with extensive anterior wall myocardial infarction (EAWMI), 4 presented with inferior wall myocardial infarction (IWMI), 1 with IWMI with complete heart block (CHB), 2 had EAWMI, 5 had inferior wall posterior wall myocardial infarction (IWPWMI), 1 had extensive inferior wall posterior wall myocardial infarction (EIWPWMI), 16 had NSTEMI, and 13 presented with UA, as shown in ►Table 3.

Out of 60 patients, 24 had single vessel disease (left anterior descending [LAD] 13, left circumflex [LCX] 2, right

coronary artery [RCA] 9), 1 had left main, triple vessel disease, 9 had triple vessel disease, 26 had double vessel disease (LAD LCX 14, LAD RCA 6, LCX RCA 6) disease. Out of 60 patients 15 patients underwent PCI to LAD, 10 patients underwent PCI to RCA, 4 underwent PCI to LCX, 8 underwent coronary artery bypass graft (CABG) surgery, and 1 underwent multivessel PCI.

In present study, the ROC curve (as shown in ►Fig. 1 below) showed cutoff value of WMR as 1059 with area under curve (AUC) of 0.6 (95% CI 0.4–0.9). The area under ROC curve is maximum at 1059 value with better sensitivity.

MACE was noted in 12 patients and mortality was noted in 6 patients. MACE like recurrent myocardial infarction (REMI) occurred in 6 patients with high WMR (> 1059) and

Table 2 Comorbidities of patients

Comorbidities	Frequency	Percent
Hypertension	36	60%
Diabetes	21	35%
Alcoholism	26	43.3%
Smoking	21	35%
Hypothyroidism	10	16.6%

Table 1 Gender distribution

Gender	Frequency	Percent
Female	24	40.00%
Male	36	60.00%
Total	60	100.00%

Abbreviations: AUC, area under curve; MACE, major adverse cardiac event; WMR, white blood cell count to mean platelet volume ratio.

Table 3 Diagnosis of patients

Diagnosis	Males	Percentage	Females	Percentage	Total	Percent
AWMI	7	11.66%	2	3.33%	9	15.00%
EAWMI	5	8.33%	3	5.00%	8	13.33%
EIWI	0	0.00%	2	3.33%	2	3.33%
EIWPWMI	1	1.66%	0	0.00%	1	1.67%
IWMI	2	3.33%	2	3.33%	4	6.67%
IWMI CHB	1	1.66%	0	0.00%	1	1.67%
IWPWMI	3	5.00%	2	3.33%	5	8.33%
NSTEMI	9	15%	7	11.66%	16	26.67%
UA	7	11.66%	6	10.00%	13	21.67%
Total	36	60.00%	24	40.00%	60	100.00%

Abbreviations: AWMI, anterior wall myocardial infarction; EAWMI, external anterior wall myocardial infarction; EIWI, external inferior wall myocardial infarction; EIWPWMI, external inferior wall posterior wall myocardial infarction; IWMI, inferior wall myocardial infarction; IWMI CHB, inferior wall myocardial infarction complete heart block; IWPWMI, inferior wall posterior wall myocardial infarction; non-ST-segment elevation myocardial infarction; UA, unstable angina.

TP - True positive rate, FP - False positive rate

Area under the ROC curve = 0.6 (0.4 - 0.9)

Fig. 1 Receiver operating characteristic (ROC) curve showing area under curve (AUC) for white blood cell count to mean platelet volume ratio (WMR) in predicting major adverse cardiac event (MACE).

in 1 patient with low WMR (< 1059), arrhythmias occurred in 4 patients with high WMR (1059) and in 1 patient with low WMR (1059), and cardiogenic shock occurred in 8 patients with high WMR (1059).

WMR with a cutoff value of 1059 was significant and highly accurate in predicting MACE with sensitivity of 91.6%, specificity of 87.5%, positive predictive value (PPV) of 64.7%, negative predictive value (NPV) of 97.6%, and diagnostic accuracy of 88.3%.

Accuracy Of WMR in Predicting MACE (Overall)

MACE occurred in 12 patients; among them, 11 patients had WMR ratio > 1059 and 1 patient had low WMR ratio < 1059, with sensitivity of 91.6%, specificity of 87.5%, PPV of 64.7%, NPV of 97.6%, and diagnostic accuracy of 88.3% (►Table 4).

Comparison of WMR Ratio in Males and Females

In the present study, 17 patients had WMR ratio > 1059; among them, 11 were males and 6 were females (►Table 5).

Accuracy of WMR in Predicting MACE in Females

MACE occurred in 12 patients; among them, 6 patients were females. Among those 6 females, 5 patients had WMR ratio > 1059 and 1 patient had low WMR ratio < 1059 with sensitivity of 83.3%, specificity of 94.4%, PPV of 83.33%, NPV of 94.44%, and diagnostic accuracy of 91.67% (►Table 6).

Comparing WMR and MACE

About 20 MACE events occurred; among them, 18 events occurred in patients with WMR ratio > 1059 and 2 patients had low WMR ratio < 1059, with sensitivity of 90%, specificity

of 37.5%, PPV of 41.6%, NPV of 88.24%, and diagnostic accuracy of 55% (►Table 7).

Various Types of Major Cardiac Events:

MACE like REMI occurred in 6 patients with high WMR (> 1059) and in 1 patient with low WMR (< 1059), arrhythmias occurred in 4 patients with high WMR (1059) and in 1 patient with low WMR (1059), and cardiogenic shock occurred in 8 patients with high WMR (1059) (►Table 8).

Major Adverse Cardiac Events

Overall, 20 MACE occurred in 12 patients. Out of them, 6 were males (10%) and 6 were females (10%). Hence, in the present study, MACE did not show any gender predilection (and 10).

Comparison of Baseline Investigations with WMR (►Table 11)

Comparison of Baseline Investigations with MACE (►Table 12)

Mean Values of Study Population (►Table 13)

Discussion

WMR is a novel noninvasive marker, which is highly accurate in predicting MACE in patients presenting with ACS. Raised WMR with cutoff value of 1059 with AUC of 0.6 (95% CI 0.4–0.9), sensitivity of 91.6%, specificity of 87.5%, PPV of 64.7%, NPV of 97.6%, and diagnostic accuracy of 88.3% ($p = 0.01$).

MACE occurred in 12 patients; among them, 6 patients were females. Compared to males, females had less sensitivity

Table 4 MACE and WMR (patients)

WMR	MACE		Total	p-Value
	Yes	No		
>1059	11	6	17	0.01 (Significant)
<= 1059	1	42	43	
Total	12	48	60(100%)	
Parameter (patients)		Estimate	Lower-upper 95% CIs	Method
Sensitivity		91.6%	(61.5–99.79)	Wilson score
Specificity		87.5%	(74.72–95.27) ¹	Wilson score
PPV		64.71%	(45.97–79.80) ¹	Wilson score
NPV		97.6%	(86.512–99.64) ¹	Wilson score
Diagnostic accuracy		88.3%	(77.43–95.18) ¹	Wilson score
Likelihood ratio of a positive test		7.33	(3.04–15.8)	
Likelihood ratio of a negative test		0.10	(0.012–0.62)	

Abbreviations: CI, confidence interval; MACE, major adverse cardiac event; NPV, negative predictive value; PPV, positive predictive value; WMR, white blood cell count to mean platelet volume ratio.

Table 5 Comparison of WMR ratio in males and females

WMR	Males	Percentage	Females	Percentage	Total	Percent
≤ 1059	25	41.66%	18	30%	43	71.66%
> 1059	11	18.33%	6	10.00%	17	28.33%
Total	36	60.00%	24	40.00%	60	100.00%

Abbreviation: WMR, white blood cell count to mean platelet volume ratio.

Table 6 MACE and WMR (female patients)

WMR	MACE		Total	p-Value
	Yes	No		
> 1059	5	1	6	0.01 (significant)
≤ 1059	1	17	18	
Total	6	18	24	
Parameter (patients)	Estimate		Lower–upper 95% CIs	Method
Sensitivity	83.3%		(35.88–99.58)	Wilson score
Specificity	94.4%		(72.71–99.86 ¹)	Wilson score
PPV	83.33%		(41.86–97.20 ¹)	Wilson score
NPV	94.44%		(73.89–99.03 ¹)	Wilson score
Diagnostic Accuracy	91.67%		(73.00–98.97 ¹)	Wilson score
Likelihood ratio of a positive test	15		(2.162–104.18)	
Likelihood ratio of a negative test	0.18		(0.03–1.06)	

Abbreviations: CI, confidence interval; MACE, major adverse cardiac event; NPV, negative predictive value; PPV, positive predictive value; WMR, white blood cell count to mean platelet volume ratio.

Table 7 MACE and WMR: (events)

WMR	MACE		Total	p-Value
	Yes	No		
> 1059	18 (30%)	25 (41.66%)	43 (71.66%)	0.01 (significant)
≤ 1059	2 (3.33%)	15 (25%)	17 (28.33%)	
Total	20 (33.33%)	40 (66.66%)	60 (100%)	
Parameter (events)	Estimate		Lower–upper 95% CIs	Method
Sensitivity	90%		(69.9–97.21 ¹)	Wilson score
Specificity	37.5%		(24.22–52.97 ¹)	Wilson score
PPV	41.86%		(28.38–56.67 ¹)	Wilson score
NPV	88.24%		(65.66–96.71 ¹)	Wilson score
Diagnostic accuracy	55%		(42.49–66.91 ¹)	Wilson score
Likelihood ratio of a positive test	1.44		(1.315–1.576)	
Likelihood ratio of a negative test	0.2667		(0.0805–0.8834)	
Diagnostic odds	5.4		(1.096–26.61)	

Abbreviations: CI, confidence interval; MACE, major adverse cardiac event; NPV, negative predictive value; PPV, positive predictive value; WMR, white blood cell count to mean platelet volume ratio.

Table 8 Various types of major cardiac events with high and low WMR

MACE	WMR		Total
	≥ 1059	< 1059	
REMI	6 (30%)	1 (5%)	7 (35%)
Arrhythmia	4 (20%)	1 (5%)	5 (25%)
Cardiogenic Shock	8 (40%)	0	8 (40%)
Total	18 (90%)	2 (10%)	20 (100%)

Abbreviations: MACE, major adverse cardiac event; REMI, recurrent myocardial infarction; WMR, white blood cell count to mean platelet volume ratio.

Table 9 MACE

MACE	No. of events	Percent
Yes	20	33.33%
No	40	66.66%
Total	60	100.00%

Abbreviation: MACE, major adverse cardiac event.

Table 10 Comparison of MACE in males and females

MACE	Males	Percentage	Females	Percentage	Total	Percent
Yes	6	10%	6	10%	12	20.00%
No	30	50.00%	18	30.00%	48	80.00%
Total	36	60.00%	24	40.00%	60	100.00%

Abbreviation: MACE, major adverse cardiac event.

Table 11 Comparison of baseline investigations with WMR

Parameter		WMR (< 1059) (n = 43)	WMR (> 1059) (n = 17)	p-Value
Complete blood picture	Age	58 ± 10.399	55.2 ± 11.71	0.3
	Hemoglobin	11.72 ± 1.27	12.511 ± 1.30	0.03 *
	WBC	9165.116 ± 1557.299	14413.529 ± 1795.79	< 0.0000001 *
	PCV	39.72 ± 5.006	42.117 ± 5.218	0.1
	PLT	1.98 ± 0.407	2.5 ± 0.306	0.00001 *
	Neutrophils	7.19 ± 1.55	11.37 ± 1.796	< 0.0000001 *
	Lymphocytes	1.62 ± 0.370	2.02 ± 0.405	0.0005 *
	MPV	10.82 ± 1.239	11.78 ± 1.449	0.01 *
Cardiac enzymes	WMR	840.34 ± 141.83	11247 ± 127.65	< 0.000001 *
	CPK-MB	259.62 ± 128.55	434.823 ± 174.86	0.00007 *
Liver enzymes	LDH	362.72 ± 167.95	573.47 ± 206.95	0.0001 *
	AST	63.62 ± 98.86	186.529 ± 317.04	0.02 *
	ALT	56.34 ± 75.146	158.647 ± 242.28	0.01 *
	ALP	205.34 ± 68.379	201.88 ± 71.37	0.8
Renal parameters	Bilirubin	1.011 ± 0.3148	1.0176 ± 0.367	0.9
	Blood urea	23.81 ± 11.11	30.117 ± 16.78	0.09
Lipid profile	Serum creatinine	0.934 ± 0.43	1.417 ± 1.067	0.01 *
	Total cholesterol	170.186 ± 55.23	202.70 ± 78.66	0.07
	LDL	120.65 ± 31.65	144.23 ± 46.866	0.03 *
	HDL	38.65 ± 3.81	36.1176 ± 4.32	0.02 *
	TG	234.093 ± 135.46	352.70 ± 158.077	0.005 *
	VLDL	40.27 ± 14.66	39.05 ± 13.325	0.7

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CPK-MB, creatine phosphokinase-MB; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; MPV, mean platelet volume; PCV, packed cell volume; PLT, platelet count; TG, triglyceride; VLDL, very low density lipoprotein; WBC, white blood cell; WMR, white blood cell count to mean platelet volume ratio.

*Pertains to statistically significant ($p \leq 0.05$).

Table 12 Comparison of baseline investigations with MACE

Parameter		MACE not reported (48)	MACE reported (12)	p-value
Complete blood picture	Age	58.0625 ± 10.78	54.33 ± 10.48	0.2
	Hemoglobin	11.745 ± 1.269	12.74 ± 1.28	0.01*
	WBC	9647.9116 ± 1906.31	14669.16 ± 2632.169	< 0.0000001*
	PCV	40 ± 4.61	42 ± 6.87	0.2
	PLT	2.066 ± 0.444	2.83 ± 0.363	0.0000007*
	Neutrophils	7.56 ± 1.77	11.55 ± 2.47	< 0.000001*
	Lymphocytes	1.63 ± 0.368	2.19 ± 0.336	0.00001*
	MPV	10.922 ± 1.22	11.925 ± 1.611	0.02*
Cardiac enzymes	WMR	889.375 ± 163.96	1220.33 ± 270.55	0.000001*
	CPK-MB	267.29 ± 132.70	477.166 ± 166.98	0.00001*
Liver enzymes	LDH	371.04 ± 171.839	628 ± 188.171	0.00002*
	AST	73.75 ± 182.54	197.25 ± 211.11	0.04*
Renal parameters	ALT	61.39 ± 119.54	181.08 ± 212.08	0.01*
	ALP	197.125 ± 63.44	233.33 ± 83.25	0.1
	Bilirubin	0.977 ± 0.269	1.158 ± 0.48	0.08
	Blood urea	23.54 ± 10.65	38.33 ± 18.64	0.0005*
Lipid profile	Serum creatinine	0.929 ± 0.408	1.64 ± 1.21	0.001*
	Total cholesterol	163.58 ± 49.83	242.666 ± 75.83	0.00004*
	LDL	117.166 ± 29.31	168 ± 41.34	0.000007*
	HDL	38.45 ± 3.89	35.83 ± 4.38	0.04*
	TGS	227.208 ± 125.56	429.66 ± 137.30	0.000007*
	VLDL	39.833 ± 14.509	40.33 ± 13.47	0.9

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CPK-MB, creatine phosphokinase-MB; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; MPV, mean platelet volume; PCV, packed cell volume; PLT, platelet count; TG, triglyceride; VLDL, very low density lipoprotein; WBC, white blood cell; WMR, white blood cell count to mean platelet volume ratio.

*Pertains to Statistically Significant ($p \leq 0.05$).

Table 13 Mean values of study population

Parameter		Mean ± SD
Complete blood picture	Hemoglobin	11.945 ± 1.32
	WBC	10652.166 ± 28779.07
	PCV	40.4 ± 5.139
	PLT	2.13 ± 0.44
	Neutrophils	8.36 ± 2.49
	Lymphocytes	1.73 ± 0.42
	MPV	11.123 ± 1.355
	WMR	955.56 ± 229.97
Cardiac enzymes	CPK-MB	309.266 ± 162.46
	LDH	422.43 ± 202.158
Liver enzymes	AST	98.45 ± 193.22
	ALT	85.33 ± 148.66
	ALP	204.366 ± 68.64
	Bilirubin	1.01 ± 0.32
Renal parameters	Blood urea	25.6 ± 13.13
	Serum creatinine	1.071 ± 0.699
Lipid profile	Total cholesterol	179.4 ± 63.78
	LDL	127.3 ± 37.73
	HDL	37.93 ± 4.09
	TGS	267.7 ± 150.8
	VLDL	39.9 ± 14.19

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CPK-MB, creatine phosphokinase-MB; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; MPV, mean platelet volume; PCV, packed cell volume; PLT, platelet count; SD, standard deviation; TG, triglyceride; VLDL, very low density lipoprotein; WBC, white blood cell; WMR, white blood cell count to mean platelet volume ratio.

to, high specificity to, and high diagnostic accuracy of WMR ratio in predicting MACE.

Overall, 20 MACE occurred in 12 patients. Out of them, 6 were males (10%) and 6 were females (10%). Hence, in the present study, MACE did not show any gender predilection.

Out of 60 patients presenting with ACS, 7 patients developed REMI (11.66%). Among them, 3 were males (5%) and 4 were females (6.66%). Compared to males, females had slight increase of incidence of REMI.

Out of 60 patients presenting with ACS, 5 patients developed arrhythmias (8.33%). Among them, 3 were males (5%) and 2 were females (3.3%). Compared to males, females had slight decrease of incidence of arrhythmias.

Out of 60 patients 8 patients developed cardiogenic shock. Among them, 4 were males (6.66%) and 4 were females (6.66%). Compared to males, females had equal incidence of cardiogenic shock.

Out of 60 patients, death occurred in 6 patients in the present study. Among them, 3 were males (5%) and 3 were females (5%). Males and females had similar death rates.

Out of 60 patients 6 patients died, and cause of death was cardiogenic shock in 5 and arrhythmia in 1 patient. Cause of death in males was cardiogenic shock, and in females, cause of death was cardiogenic shock and arrhythmia.

Along with WMR, higher WBC and higher neutrophil count were other predictors of MACE.

WMR is a ratio derived from WBC count to MPV ratio. In the present study, baseline MPV level in patients with MACE was 11.78 ± 1.449 , and in patients without MACE, it was 10.82 ± 1.239 .

In the present study, mean WBC count was found significantly high in patients with MACE (14669.16 ± 2632.169) than those without MACE (9647.9116 ± 1906.31) and the difference was significant ($p < 0.0001$). An increased WBC count is a prominent indicator of compromised microvascular reperfusion. Barron et al presented that acute MI patients with a leucocyte count in the highest quintile had a higher 30-day mortality rate than patients with a leucocyte count in the lower quintiles.¹⁵ In the present study, it was also found that increased WBC count was associated with MACE.

The present study demonstrated that raised WMR, that is with a cutoff value of 1059, holds greater predictive value for short-term MACE in patients presenting with ACS, yielding higher diagnostic accuracy (88.3%), sensitivity (91%), specificity (87.5%) with low PPV (64.7%) and high NPV (97.6%) as well as high positive likelihood ratio (7.33) and lower negative likelihood ratio (0.10) ($p = 0.01$). Recently, Adam et al reported sensitivity of 68.3% and specificity of 63.7% with slightly higher WMR cutoff values (1068.75, AUC = 0.734 95% CI: 0.656–0.812; $p < 0.001$), which is very much comparable with the present study.

The present study results show that WMR had a higher sensitivity to predict short-term outcomes; therefore, calculating WMR is not only sensitive but a faster and a more efficient marker.

Overall, the present study demonstrates that raised WMR (≥ 1059) is highly accurate in discriminating poor outcome, that is, MACE within 30 days of patients presenting with ACS.

However, these conclusions require careful interpretation due to potential limitations of this study

Limitations of this Study

The conclusions drawn from the present study were based on a single-centre study comprising a relatively smaller sample size, using a nonrandomized sampling technique. Furthermore, we did not measure other more specific proinflammatory markers, including P-selectin, high-sensitivity C-reactive protein (CRP), interleukins, selectin molecules, adhesion ligands and receptors, and markers of oxidative stress to show any comparison between WMR and such biomarkers. Further studies are required to validate these results and define the exact role of WMR in predicting short-term MACE.

Conclusion

In patients who presented with ACS, high WMR values were associated with worse short-term outcomes and independently predicted short-term MACE. Compared to males, females had less sensitivity, high specificity, and high diagnostic accuracy of WMR ratio in predicting MACE.

Audio

Audio file for this article is available at <https://doi.org/10.1055/s-0041-1732513>.

Conflict of Interest

None declared.

References

- 1 Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet* 1997;349(9061): 1269–1276
- 2 Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. *Heart* 2008;94(1):16–26
- 3 Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med* 2013;368(21):2004–2013
- 4 Margolis KL, Manson JE, Greenland P, et al. Women's Health Initiative Research Group. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. *Arch Intern Med* 2005;165(5):500–508
- 5 Rognoni A, Cavallino C, Veia A, et al. Pathophysiology of atherosclerotic plaque development. *Cardiovasc Hematol Agents Med Chem* 2015;13(1):10–13

- 6 Horne BD, Anderson JL, John JM, et al. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? *J Am Coll Cardiol* 2005;45(10):1638–1643
- 7 Davì G, Patrono C. Platelet activation and atherothrombosis. *N Engl J Med* 2007;357(24):2482–2494
- 8 Dehghani MR, Rezaei Y, Fakour S, Arjmand N. White blood cell count to mean platelet volume ratio is a prognostic factor in patients with non-ST elevation acute coronary syndrome with or without metabolic syndrome. *Korean Circ J* 2016;46(2):229–238
- 9 Adam AM, Rizvi AH, Haq A, et al. Prognostic value of blood count parameters in patients with acute coronary syndrome. *Indian Heart J* 2018;70(2):233–240
- 10 Dehghani MR, Rezaei Y, Taghipour-Sani L. White blood cell count to mean platelet volume ratio as a novel non-invasive marker predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome. *Cardiol J* 2015;22(4):437–445
- 11 Mello BH, Oliveira GB, Ramos RF, et al. Validation of the Killip-Kimball classification and late mortality after acute myocardial infarction. *Arq Bras Cardiol* 2014;103(2):107–117
- 12 Raphael C, Briscoe C, Davies J, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. *Heart* 2007;93(4):476–482
- 13 Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J* 2007;28(20):2525–2538
- 14 Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, Harrison's Principles of Internal Medicine, New York, NY: McGraw-Hill Companies; 2015
- 15 Barron HV, Harr SD, Radford MJ, Wang Y, Krumholz HM. The association between white blood cell count and acute myocardial infarction mortality in patients > or =65 years of age: findings from the cooperative cardiovascular project. *J Am Coll Cardiol* 2001;38(6):1654–1661